Neuroprotection in Miscellaneous Neurological Disorders

  • Kewal K. Jain
Part of the Springer Protocols Handbooks book series (SPH)


Several neurological disorders that are not covered in the preceding chapters result in damage to the brain requiring neuroprotection. In addition to this several systemic disorders have neurological manifestations due to damage to the nervous system. Nuroprotective strategies for these disorders are also described in this chapter.


  1. Abou-Donia MB, Siracuse B, Gupta N, Sobel Sokol A. Sarin (GB, O-isopropyl methylphosphonofluoridate) neurotoxicity: critical review. Crit Rev Toxicol 2016;46:845-75.PubMedPubMedCentralCrossRefGoogle Scholar
  2. Agrawal L, Louboutin JP, Strayer DS. Preventing HIV-1 Tat-induced neuronal apoptosis using antioxidant enzymes: mechanistic and therapeutic implications. Virology 2007;363:462-72.PubMedCrossRefPubMedCentralGoogle Scholar
  3. Alonso-Alconada D, Alvarez A, Arteaga O, et al. Neuroprotective effect of melatonin: a novel therapy against perinatal hypoxia-ischemia. Int J Mol Sci 2013;14:9379-95.PubMedPubMedCentralCrossRefGoogle Scholar
  4. Apoorv TS, Babu PP. Minocycline prevents cerebral malaria, confers neuroprotection and increases survivability of mice during Plasmodium berghei ANKA infection. Cytokine 2017;90:113-123.PubMedCrossRefPubMedCentralGoogle Scholar
  5. Arango-Lievano M, Lambert M, Bath KG, et al. Neurotrophic-priming of glucocorticoid receptor signaling is essential for neuronal plasticity to stress and antidepressant treatment. Proc Natl Acad Sci U S A 2015;112:15737-42.PubMedPubMedCentralGoogle Scholar
  6. Arranz AM, Perkins KL, Irie F, et al. Hyaluronan deficiency due to Has3 knock-out causes altered neuronal activity and seizures via reduction in brain extracellular space. J Neurosci 2014; 34: 6164-76.PubMedPubMedCentralCrossRefGoogle Scholar
  7. Arrich J, Holzer M, Havel C, et al. Pre-hospital versus in-hospital initiation of cooling for survival and neuroprotection after out-of-hospital cardiac arrest. Cochrane Database Syst Rev 2016;3:CD010570.PubMedPubMedCentralGoogle Scholar
  8. Atamna H, Nguyen A, Schultz C, et al. Methylene blue delays cellular senescence and enhances key mitochondrial biochemical pathways. FASEB J 2008;22:703-12.PubMedCrossRefPubMedCentralGoogle Scholar
  9. Atkins HL, Bowman M, Allan D, et al. Immunoablation and autologous haemopoietic stem-cell transplantation for aggressive multiple sclerosis: a multicentre single-group phase 2 trial. Lancet 2016;388:576-85.PubMedCrossRefPubMedCentralGoogle Scholar
  10. Axelson HW, Oberg G, Askmark H. Successful repeated treatment with high dose cyclophosphamide and autologous blood stem cell transplantation in CIDP. J Neurol Neurosurg Psychiatry 2008;79:612-4.CrossRefGoogle Scholar
  11. Azzopardi DV, Strohm B, Edwards AD, et al. Moderate Hypothermia to Treat Perinatal Asphyxial Encephalopathy. N Engl J Med 2009 361: 1349-58.PubMedCrossRefGoogle Scholar
  12. Bachewal P, Gundu C, Yerra VG, et al. Morin exerts neuroprotection via attenuation of ROS induced oxidative damage and neuroinflammation in experimental diabetic neuropathy. Biofactors 2018;44:109-122.PubMedCrossRefGoogle Scholar
  13. Bai L, Lennon DP, Caplan AI, et al. Hepatocyte growth factor mediates mesenchymal stem cell-induced recovery in multiple sclerosis models. Nat Neurosci 2012;15:862-70.PubMedPubMedCentralCrossRefGoogle Scholar
  14. Baker D, Marta M, Pryce G, et al. Memory B Cells are Major Targets for Effective Immunotherapy in Relapsing Multiple Sclerosis. EBioMedicine 2017;16:41-50.PubMedPubMedCentralCrossRefGoogle Scholar
  15. Barkhof F, de Jong R, Sfikas N, et al. The influence of patient demographics, disease characteristics and treatment on brain volume loss in Trial Assessing Injectable Interferon vs FTY720 Oral in Relapsing-Remitting Multiple Sclerosis (TRANSFORMS), a phase 3 study of fingolimod in multiple sclerosis. Mult Scler 2014;20:1704-13.PubMedCrossRefGoogle Scholar
  16. Barkhof F, Hulst HE, Drulovic J, et al. Ibudilast in relapsing-remitting multiple sclerosis: a neuroprotectant? Neurology 2010;74:1033-40.PubMedCrossRefGoogle Scholar
  17. Barzegar-Fallah A, Alimoradi H, Mehrzadi S, et al. The neuroprotective effect of tropisetron on vincristine-induced neurotoxicity. Neurotoxicology 2014;41:1-8.PubMedCrossRefGoogle Scholar
  18. Bekenstein U, Mishra N, Milikovsky DZ, et al. Dynamic changes in murine forebrain miR-211 expression associate with cholinergic imbalances and epileptiform activity. Proc Natl Acad Sci U S A 2017;114:E4996-E5005.PubMedPubMedCentralCrossRefGoogle Scholar
  19. Bever CT, Judge SI. Sustained-release fampridine for multiple sclerosis. Expert Opin Investig Drugs 2009;18:1013-24.PubMedCrossRefGoogle Scholar
  20. Bloss EB, Hunter RG, Waters EM, et al. Behavioral and biological effects of chronic S18986, a positive AMPA receptor modulator, during aging. Exp Neurol 2008;210:109-17.PubMedCrossRefPubMedCentralGoogle Scholar
  21. Bobkova NV, Evgen’ev M, Garbuz DG, et al. Exogenous Hsp70 delays senescence and improves cognitive function in aging mice. Proc Natl Acad Sci U S A 2015;112:16006-11.PubMedPubMedCentralCrossRefGoogle Scholar
  22. Boyke J, Driemeyer J, Gaser C, Büchel C, May A. Training-induced brain structure changes in the elderly. J Neurosci 2008;28:7031-5.PubMedCrossRefGoogle Scholar
  23. Brandt-Wouters E, Gerlach OH, Hupperts RM. The effect of postpartum intravenous immunoglobulins on the relapse rate among patients with multiple sclerosis. Int J Gynaecol Obstet 2016;134:194-6.PubMedCrossRefPubMedCentralGoogle Scholar
  24. Broad KD, Keverne KB. Placental protection of the fetal brain during short-term food deprivation. Proc Natl Acad Sci U S A 2011;108:15237-41.PubMedPubMedCentralCrossRefGoogle Scholar
  25. Brock PR, Maibach R, Childs M, et al. Sodium Thiosulfate for Protection from Cisplatin-Induced Hearing Loss. N Engl J Med 2018; 378:2376-85.PubMedPubMedCentralCrossRefGoogle Scholar
  26. Bui AD, Nguyen TM, Limouse C, et al. Dentate gyrus mossy cells control spontaneous convulsive seizures and spatial memory. Science 2018;359:787-90.PubMedPubMedCentralCrossRefGoogle Scholar
  27. Burt RK, Loh Y, Cohen B, et al. Autologous non-myeloablative haemopoietic stem cell transplantation in relapsing-remitting multiple sclerosis: a phase I/II study. Lancet Neurol 2009;8:244-53.PubMedCrossRefPubMedCentralGoogle Scholar
  28. Caprariello AV, Rogers JA, Morgan ML, et al. Biochemically altered myelin triggers autoimmune demyelination. Proc Natl Acad Sci U S A 2018;115:5528-5533.PubMedPubMedCentralCrossRefGoogle Scholar
  29. Carbajal KS, Schaumburg C, Strieter R, et al. Migration of engrafted neural stem cells is mediated by CXCL12 signaling through CXCR4 in a viral model of multiple sclerosis. PNAS 2010;107:11068-73.PubMedCrossRefPubMedCentralGoogle Scholar
  30. Casals-Pascual C, Idro R, Gicheru N, et al. High levels of erythropoietin are associated with protection against neurological sequelae in African children with cerebral malaria. PNAS 2008;105:2634-9.PubMedCrossRefPubMedCentralGoogle Scholar
  31. Chan D, Binks S, Nicholas JM, et al. Effect of high-dose simvastatin on cognitive, neuropsychiatric, and health-related quality-of-life measures in secondary progressive multiple sclerosis: secondary analyses from the MS-STAT randomised, placebo-controlled trial. Lancet Neurol 2017;16:591-600.PubMedPubMedCentralCrossRefGoogle Scholar
  32. Chao LL, Abadjian L, Hlavin J, et al. Effects of low-level sarin and cyclosarin exposure and Gulf War Illness on brain structure and function: a study at 4T. Neurotoxicology 2011;32:814-22.PubMedCrossRefPubMedCentralGoogle Scholar
  33. Chen B, Li J, Borgens R, et al. Neuroprotection by chitosan nanoparticles in oxidative stress-mediated injury. BMC Res Notes 2018;11:49.PubMedPubMedCentralCrossRefGoogle Scholar
  34. Chen LY, Rex CS, Sanaiha Y, et al. Learning induces neurotrophin signaling at hippocampal synapses. Proc Natl Acad Sci U S A 2010;107:7030-5.PubMedPubMedCentralCrossRefGoogle Scholar
  35. Choi JW, Gardell SE, Herr DR, et al. FTY720 (fingolimod) efficacy in an animal model of multiple sclerosis requires astrocyte sphingosine 1-phosphate receptor 1 (S1P1) modulation. PNAS 2011;108:751-6.PubMedCrossRefPubMedCentralGoogle Scholar
  36. Choi YH, Miller JM, Tucker KL, et al. Antioxidant vitamins and magnesium and the risk of hearing loss in the US general population. Am J Clin Nutr 2014;99:148-55.PubMedCrossRefPubMedCentralGoogle Scholar
  37. Cohen JA, Barkhof F, Comi G, for the TRANSFORMS Study Group. Oral Fingolimod or Intramuscular Interferon for Relapsing Multiple Sclerosis. NEJM 2010;362:402-15.Google Scholar
  38. Comi G, Pulizzi A, Rovaris M, et al. Effect of laquinimod on MRI-monitored disease activity in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study. Lancet 2008;371:2085-92.PubMedCrossRefPubMedCentralGoogle Scholar
  39. Crowther CA, Middleton PF, Voysey M, et al. Assessing the neuroprotective benefits for babies of antenatal magnesium sulphate: An individual participant data meta-analysis. PLoS Med 2017;14(10): e1002398.PubMedPubMedCentralCrossRefGoogle Scholar
  40. Dallari S, Franciotta D, Carluccio S, et al. Upregulation of integrin expression on monocytes in multiple sclerosis patients treated with natalizumab. J Neuroimmunol 2015;287:76-9.PubMedCrossRefPubMedCentralGoogle Scholar
  41. De Benedetti F, Gattorno M, Anton J, et al. Canakinumab for the Treatment of Autoinflammatory Recurrent Fever Syndromes. N Engl J Med 2018; 378:1908-19.PubMedPubMedCentralCrossRefGoogle Scholar
  42. DeBoy CA, Rus H, Tegla C, et al. FLT-3 expression and function on microglia in multiple sclerosis. Exp Mol Pathol 2010;89:109-16.PubMedPubMedCentralCrossRefGoogle Scholar
  43. Del Bigio MR, Di Curzio DL. Nonsurgical therapy for hydrocephalus: a comprehensive and critical review. Fluids Barriers CNS 2016;13:3.PubMedPubMedCentralCrossRefGoogle Scholar
  44. Dell’anna AM, Scolletta S, Donadello K, Taccone FS. Early neuroprotection after cardiac arrest. Curr Opin Crit Care 2014;20:250-8.PubMedCrossRefPubMedCentralGoogle Scholar
  45. Dezfulian C, Kenny E, Lamade A, et al. Mechanistic characterization of nitrite-mediated neuroprotection after experimental cardiac arrest. J Neurochem 2016;139:419-31.PubMedPubMedCentralCrossRefGoogle Scholar
  46. Dietrich P, Shanmugasundaram R, Shuyu E, Dragatsis I. Congenital hydrocephalus associated with abnormal subcommissural organ in mice lacking huntingtin in Wnt1 cell lineages. Hum Mol Genet 2009;18:142-50.PubMedCrossRefPubMedCentralGoogle Scholar
  47. Duplessis CA, Fothergill D. Investigating the potential of statin medications as a nitric oxide (NO) release agent to decrease decompression sickness: a review article. Med Hypotheses 2008;70:560-6.PubMedCrossRefPubMedCentralGoogle Scholar
  48. Echouffo-Tcheugui JB, Conner SC, Himali JJ, et al. Circulating cortisol and cognitive and structural brain measures: The Framingham Heart Study. Neurology 2018;91:e1961-e1970.CrossRefGoogle Scholar
  49. Elfar JC, Jacobson JA, Puzas JE, et al. Erythropoietin accelerates functional recovery after peripheral nerve injury. J Bone Joint Surg Am 2008;90:1644-53.PubMedPubMedCentralCrossRefGoogle Scholar
  50. Farez MF, Mascanfroni ID, Méndez-Huergo SP, et al. Melatonin Contributes to the Seasonality of Multiple Sclerosis Relapses. Cell 2015;162:1338-52.PubMedPubMedCentralCrossRefGoogle Scholar
  51. Fauchère JC, Dame C, Vonthein R, et al. An approach to using recombinant erythropoietin for neuroprotection in very preterm infants. Pediatrics 2008;122:375-82.PubMedCrossRefPubMedCentralGoogle Scholar
  52. Feng Z, Liu J, Ju R, et al. Hyperbaric oxygen treatment promotes neural stem cell proliferation in the subventricular zone of neonatal rats with hypoxic-ischemic brain damage. Neural Regeneration Research 2013;8:1220-7.PubMedPubMedCentralGoogle Scholar
  53. Fledrich R, Rasch L, Abdelaal T, et al. Targeting myelin lipid metabolism as a potential therapeutic strategy in a model of CMT1A neuropathy. Nat Commun 2018;9:3025.PubMedPubMedCentralCrossRefGoogle Scholar
  54. Fox RJ, Coffey CS, Conwit R, et al. Phase 2 Trial of Ibudilast in Progressive Multiple Sclerosis. N Engl J Med 2018; 379:846-855.PubMedPubMedCentralCrossRefGoogle Scholar
  55. Fox RJ, Kita M, Cohan SL, et al. BG-12 (dimethyl fumarate): a review of mechanism of action, efficacy, and safety. Curr Med Res Opin 2014;30:251-62.PubMedCrossRefPubMedCentralGoogle Scholar
  56. Garcia CAB, Catalão CHR, Machado HR, et al. Edaravone reduces astrogliosis and apoptosis in young rats with kaolin-induced hydrocephalus. Childs Nerv Syst 2017;33:419-428.PubMedCrossRefPubMedCentralGoogle Scholar
  57. Geffin R, Martinez R, de Las Pozas A, Issac B, McCarthy M. Fingolimod induces neuronal-specific gene expression with potential neuroprotective outcomes in maturing neuronal progenitor cells exposed to HIV. J Neurovirol 2017;23:808-824.PubMedPubMedCentralCrossRefGoogle Scholar
  58. Giovannoni G, Comi G, Cook S, et al, for the CLARITY Study Group. A Placebo-Controlled Trial of Oral Cladribine for Relapsing Multiple Sclerosis. NEJM 2010;362:416-26.PubMedCrossRefPubMedCentralGoogle Scholar
  59. Goodman AD, Brown TR, Krupp LB, et al. Sustained-release oral fampridine in multiple sclerosis: a randomised, double-blind, controlled trial. Lancet 2009;373:732-8.PubMedCrossRefPubMedCentralGoogle Scholar
  60. Gopinath B, Flood VM, Rochtchina E, et al. Consumption of omega-3 fatty acids and fish and risk of age-related hearing loss. Am J Clin Nutr 2010;92:416-21.PubMedCrossRefPubMedCentralGoogle Scholar
  61. Guenther U, Varelmann D, Putensen C, Wrigge H. Extended therapeutic hypothermia for several days during extracorporeal membrane-oxygenation after drowning and cardiac arrest: two cases of survival with no neurological sequelae. Resuscitation 2009;80:379-81.PubMedCrossRefPubMedCentralGoogle Scholar
  62. Hafler DA, Compston A, Sawcer S, et al. Risk alleles for multiple sclerosis identified by a genomewide study. N Engl J Med 2007;357:851-62.PubMedPubMedCentralCrossRefGoogle Scholar
  63. Hamana A, Takahashi Y, Tanioka A, et al. Safe and effective interferon-beta gene therapy for the treatment of multiple sclerosis by regulating biological activity through the design of interferon-beta-galectin-9 fusion proteins. Int J Pharm 2018;536:310-317.PubMedCrossRefPubMedCentralGoogle Scholar
  64. Hamer M, Sharma N, Batty GD. Association of objectively measured physical activity with brain structure: UK Biobank study. J Intern Med 2018;284:439-443.PubMedCrossRefPubMedCentralGoogle Scholar
  65. Hauser SL, Bar-Or A, Comi G, et al. Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis. N Engl J Med 2017;376:221-234.PubMedCrossRefPubMedCentralGoogle Scholar
  66. Heinrich UR, Fischer I, Brieger J, et al. Ascorbic acid reduces noise-induced nitric oxide production in the guinea pig ear. Laryngoscope 2008;118:837-42.PubMedCrossRefPubMedCentralGoogle Scholar
  67. Hernández C, Simó R. Neuroprotection in diabetic retinopathy. Curr Diab Rep 2012;12:329-37.PubMedCrossRefPubMedCentralGoogle Scholar
  68. Ho YJ, Weng JC, Lin CL, et al. Ceftriaxone Treatment for Neuronal Deficits: A Histological and MEMRI Study in a Rat Model of Dementia with Lewy Bodies. Behav Neurol 2018;2018:4618716.PubMedPubMedCentralCrossRefGoogle Scholar
  69. Holm H, Nägg K, Ricci F, et al. Biomarkers of microvascular endothelial dysfunction predict incident dementia: a population-based prospective study. J Int Med 2017;282:94-101.CrossRefGoogle Scholar
  70. Huang ZL, Pandya D, Banta DK, et al. Cyclophilin inhibitor NIM811 ameliorates experimental allergic encephalomyelitis. J Neuroimmunol 2017;311:40-48.PubMedCrossRefPubMedCentralGoogle Scholar
  71. Hughes RA, Donofrio P, Bril V, et al. Intravenous immune globulin (10% caprylate-chromatography purified) for the treatment of chronic inflammatory demyelinating polyradiculoneuropathy (ICE study): a randomised placebo-controlled trial. Lancet Neurol 2008;7:136-44.PubMedCrossRefPubMedCentralGoogle Scholar
  72. Iaffaldano P, Ribatti D, Trojano M. Natalizumab reduces serum pro-angiogenic activity in MS patients. Neurol Sci 2018;39:725-731.PubMedCrossRefPubMedCentralGoogle Scholar
  73. Ieraci A, Herrera DG. Nicotinamide Protects against Ethanol-Induced Apoptotic Neurodegeneration in the Developing Mouse Brain. PLoS Medicine 2006;3:e101.PubMedPubMedCentralCrossRefGoogle Scholar
  74. Jain KK. Carbon monoxide poisoning. Green, St. Louis (MO), 1990.Google Scholar
  75. Jain KK. Textbook of Hyperbaric Medicine, 6th ed. Springer, New York 2017.Google Scholar
  76. Jain KK. Cell Therapy. Jain PharmaBiotech Publications, Basel, Switzerland, 2019g.Google Scholar
  77. Jain KK. Dalframpidine. In, Roos RP (ed) MedLink Neurology. Medlink Publishing Corporation, San Diego, California, 2019b.Google Scholar
  78. Jain KK. Drug-induced Neurological Disorders. 3rd edition, Hogrefe, Göttingen, 2012.Google Scholar
  79. Jain KK. Fever: neurologic causes and complications. In, Roos RP (ed) MedLink Neurology. Medlink Publishing Corporation, San Diego, California, 2019h.Google Scholar
  80. Jain KK. Fingolimod. In, Roos RP (ed) MedLink Neurology. Medlink Publishing Corporation, San Diego, California, 2019c.Google Scholar
  81. Jain KK. Hepatic encephalopathy. In, Roos RP (ed) MedLink Neurology. Medlink Publishing Corporation, San Diego, California, 2019f.Google Scholar
  82. Jain KK. Mitoxantrone. In, Roos RP (ed) MedLink Neurology. Medlink Publishing Corporation, San Diego, California, 2019a.Google Scholar
  83. Jain KK. Natalizumab. In, Roos RP (ed) MedLink Neurology. Medlink Publishing Corporation, San Diego, California, 2019d.Google Scholar
  84. Jain KK. Neurologic aspects of carbon monoxide poisoning. In, Roos RP (ed) MedLink Neurology. Medlink Publishing Corporation, San Diego, California, 2019i.Google Scholar
  85. Jain KK. Neurologic disorders of aging. In, Roos RP (ed) MedLink Neurology. Medlink Publishing Corporation, San Diego, California, 2019.Google Scholar
  86. Jain KK. Neurological complications of decompression sickness. In Roos RP (ed) MedLink Neurology. Medlink Publishing Corporation, San Diego, California, 2019e.Google Scholar
  87. Jain KK. Peripheral neuropathies: treatment with neurotrophic factors. In, Roos RP (ed) MedLink Neurology. Medlink Publishing Corporation, San Diego, California, 2019j.Google Scholar
  88. James PB, Jain KK. Decompression sickness. In, Jain KK. Textbook of Hyperbaric Medicine. 6th edition, Springer, 2017.Google Scholar
  89. Janelsins MC, Roscoe JA, Berg MJ, et al. IGF-1 partially restores chemotherapy-induced reductions in neural cell proliferation in adult C57BL/6 mice. Cancer Invest 2010;28:544-53.PubMedPubMedCentralCrossRefGoogle Scholar
  90. Jellinger KA, Lantos PL. Papp-Lantos inclusions and the pathogenesis of multiple system atrophy: an update. Acta Neuropathol 2010;119:657-67.PubMedCrossRefPubMedCentralGoogle Scholar
  91. Jeong JO, Kim MO, Kim H, et al. Dual Angiogenic and Neurotrophic Effects of Bone Marrow-Derived Endothelial Progenitor Cells on Diabetic Neuropathy. Circulation 2009;119:699-708.PubMedPubMedCentralCrossRefGoogle Scholar
  92. Kalinin S, Polak PE, Lin SX, et al. Dimethyl fumarate regulates histone deacetylase expression in astrocytes. J Neuroimmunol 2013;263:13-9.PubMedCrossRefPubMedCentralGoogle Scholar
  93. Kamiya K, Fujinami Y, Hoya N, et al. Mesenchymal stem cell transplantation accelerates hearing recovery through the repair of injured cochlear fibrocytes. Am J Pathol 2007;171: 214-26.PubMedPubMedCentralCrossRefGoogle Scholar
  94. Kapoor R, Furby J, Hayton T, et al. Lamotrigine for neuroprotection in secondary progressive multiple sclerosis: a randomised, double-blind, placebo-controlled, parallel-group trial. Lancet Neurol 2010;9:681-8.PubMedCrossRefPubMedCentralGoogle Scholar
  95. Kappos L, Antel J, Comi G, et al. Oral fingolimod (FTY720) for relapsing multiple sclerosis. N Engl J Med 2006;355:1124-40.PubMedCrossRefPubMedCentralGoogle Scholar
  96. Kappos L, Radue EW, O’Connor P, et al, for the FREEDOMS Study Group. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. NEJM 2010;362:387-401.Google Scholar
  97. Kappos L, Wiendl H, Selmaj K, et al. Daclizumab HYP versus Interferon Beta-1a in Relapsing Multiple Sclerosis. N Engl J Med 2015;373:1418-28.PubMedCrossRefPubMedCentralGoogle Scholar
  98. Kaster MP, Machado NJ, Silva HB, et al. Caffeine acts through neuronal adenosine A2A receptors to prevent mood and memory dysfunction triggered by chronic stress. Proc Natl Acad Sci U S A 2015;112:7833-8.PubMedPubMedCentralCrossRefGoogle Scholar
  99. Kaur G, Trowsdale J, Fugger L. Natural killer cells and their receptors in multiple sclerosis. Brain 2013;136(Pt 9):2657-76.PubMedCrossRefGoogle Scholar
  100. Keeler GD, Kumar S, Palaschak B, et al. Gene Therapy-Induced Antigen-Specific Tregs Inhibit Neuro-inflammation and Reverse Disease in a Mouse Model of Multiple Sclerosis. Mol Ther 2018;26:173-183.PubMedCrossRefGoogle Scholar
  101. Kessler JA, Smith AG, Cha BS, et al. Double-blind, placebo-controlled study of HGF gene therapy in diabetic neuropathy. Ann Clin Transl Neurol 2015;2:465-78.PubMedPubMedCentralCrossRefGoogle Scholar
  102. Koivisto A, Alafuzoff I, Savolainen S, et al. Poor Cognitive Outcome in Shunt-Responsive Idiopathic Normal Pressure Hydrocephalus. Neurosurgery 2013;72:1-8.PubMedCrossRefGoogle Scholar
  103. Korabecny J, Soukup O, Dolezal R, et al. From pyridinium-based to centrally active acetylcholinesterase reactivators. Mini Rev Med Chem 2014;14:215-21.PubMedCrossRefGoogle Scholar
  104. Kuppermann N, Ghetti S, Schunk JE, et al. Clinical trial of fluid infusion rates for pediatric diabetic ketoacidosis. N Engl J Med 2018;378:2275-87.PubMedPubMedCentralCrossRefGoogle Scholar
  105. Lanz TV, Becker S, Osswald M, et al. Protein kinase Cβ as a therapeutic target stabilizing blood–brain barrier disruption in experimental autoimmune encephalomyelitis. Proc Natl Acad Sci U S A 2013;110:14735-40.PubMedPubMedCentralCrossRefGoogle Scholar
  106. Lazar S, Egoz I, Brandeis R, Chapman S, Bloch-Shilderman E, Grauer E. Propagation of damage in the rat brain following sarin exposure: differential progression of early processes. Toxicol Appl Pharmacol 2016;310:87-97.PubMedCrossRefPubMedCentralGoogle Scholar
  107. Lee DH, Rötger C, Appeldoorn CC, et al. Glutathione PEGylated liposomal methylprednisolone (2B3-201) attenuates CNS inflammation and degeneration in murine myelin oligodendrocyte glycoprotein induced experimental autoimmune encephalomyelitis. J Neuroimmunol 2014;274:96-101.PubMedCrossRefPubMedCentralGoogle Scholar
  108. Legriel S, Lemiale V, Schenck M, et al. Hypothermia for Neuroprotection in Convulsive Status Epilepticus. N Engl J Med 2016; 375:2457-67.PubMedCrossRefPubMedCentralGoogle Scholar
  109. Leon J, Moreno AJ, Garay BI, et al. Peripheral elevation of a Klotho fragment enhances brain function and resilience in young, aging, and a-synuclein transgenic mice. Cell Rep 2017;20:1360-71.PubMedPubMedCentralCrossRefGoogle Scholar
  110. Lepeta K, Lourenco MV, Schweitzer BC, et al. Synaptopathies: synaptic dysfunction in neurological disorders. J Neurochem 2016;138:785-805.PubMedPubMedCentralCrossRefGoogle Scholar
  111. Li R, Rezk A, Miyazaki Y, et al. Proinflammatory GM-CSF–producing B cells in multiple sclerosis and B cell depletion therapy. Science Translational Medicine 2015;7:310ra166.PubMedCrossRefPubMedCentralGoogle Scholar
  112. Liao AC, Craver BM, Tseng BP, et al. Mitochondrial-targeted human catalase affords neuroprotection from proton irradiation. Radiat Res 2013;180:1-6.PubMedCrossRefPubMedCentralGoogle Scholar
  113. Lin CH, Sheu WH. Hypoglycaemic episodes and risk of dementia in diabetes mellitus: 7-year follow-up subjects. J Int Med 2013;273:102-10.CrossRefGoogle Scholar
  114. Liu CY, Zhu J, Zheng XY, et al. Anti-N-Methyl-D-aspartate Receptor Encephalitis: A Severe, Potentially Reversible Autoimmune Encephalitis. Mediators Inflamm 2017;2017:6361479.PubMedPubMedCentralGoogle Scholar
  115. Liu-Ambrose T, Eng JJ, Boyd LA, et al. Promotion of the Mind Through Exercise (PROMoTE): A Proof-of-Concept Randomized Controlled Trial of Aerobic Exercise Training in Older Adults with Vascular Cognitive Impairment. BMC Neurology 2010;10:14.PubMedPubMedCentralCrossRefGoogle Scholar
  116. Lu T, Aron L, Zullo J, et al. REST and stress resistance in ageing and Alzheimer’s disease. Nature 2014;507:448-54.PubMedPubMedCentralCrossRefGoogle Scholar
  117. Lundgaard I, Wang W, Eberhardt A, et al. Beneficial effects of low alcohol exposure, but adverse effects of high alcohol intake on glymphatic function. Sci Rep 2018;8:2246.PubMedPubMedCentralCrossRefGoogle Scholar
  118. Luo J, Bavencoffe A, Yang P, et al. Zinc inhibits TRPV1 to alleviate chemotherapy-induced neuropathic pain. J Neurosci 2018;38:474-83.PubMedPubMedCentralCrossRefGoogle Scholar
  119. Luo J. Lithium-mediated protection against ethanol neurotoxicity. Front Neurosci 2010;4:41.PubMedPubMedCentralGoogle Scholar
  120. Lutterotti A, Yousef S, Sputtek A, et al. Antigen-specific tolerance by autologous myelin peptide-coupled cells: a phase 1 trial in multiple sclerosis. Sci Transl Med 2013;5:188ra75PubMedPubMedCentralCrossRefGoogle Scholar
  121. Mancardi G, Saccardi R. Autologous haematopoietic stem-cell transplantation in multiple sclerosis. Lancet Neurol 2008;7:626-36.PubMedCrossRefPubMedCentralGoogle Scholar
  122. Mansilla A, Chaves-Sanjuan A, Campillo NE, et al. Interference of the complex between NCS-1 and Ric8a with phenothiazines regulates synaptic function and is an approach for fragile X syndrome. Proc Natl Acad Sci U S A 2017;114:E999-E1008.PubMedPubMedCentralCrossRefGoogle Scholar
  123. Martina BEE, Smreczak M, Orlowska A, et al. Combination drug treatment prolongs survival of experimentally infected mice with silver-haired bat rabies virus. Vaccine 2018 May 26; pii: S0264-410X(18)30705-9.Google Scholar
  124. Masino SA, Li T, Theofilas P, et al. A ketogenic diet suppresses seizures in mice through adenosine A1 receptors. J Clin Invest 2011;121:2679-83.PubMedPubMedCentralCrossRefGoogle Scholar
  125. Mattoscio M, Nicholas R, Sormani MP, et al. Hematopoietic mobilization: potential biomarker of response to natalizumab in multiple sclerosis. Neurology 2015;84:1473-82.PubMedPubMedCentralCrossRefGoogle Scholar
  126. Mercey G, Verdelet T, Renou J, et al. Reactivators of acetylcholinesterase inhibited by organophosphorus nerve agents. Acc Chem Res 2012;45:756-66.PubMedCrossRefPubMedCentralGoogle Scholar
  127. Metz LM, Li DKB, Traboulsee AL, et al. Trial of Minocycline in a Clinically Isolated Syndrome of Multiple Sclerosis. N Engl J Med 2017;376:2122-33.PubMedCrossRefPubMedCentralGoogle Scholar
  128. Milena Z. Adzemovic, Manuel Zeitelhofer, Ulf Eriksson, Tomas Olsson, Ingrid Nilsson. Imatinib Ameliorates Neuroinflammation in a Rat Model of Multiple Sclerosis by Enhancing Blood-Brain Barrier Integrity and by Modulating the Peripheral Immune Response. PLoS ONE 2013; 8 (2): e56586CrossRefGoogle Scholar
  129. Miller AE. Oral teriflunomide in the treatment of relapsing forms of multiple sclerosis: clinical evidence and long-term experience. Ther Adv Neurol Disord 2017;10:381-396.PubMedPubMedCentralCrossRefGoogle Scholar
  130. Minagar A, Alexander JS, Sahraian MA, Zivadinov R. Alemtuzumab and multiple sclerosis: therapeutic application Expert Opin Biol Ther 2010;10:421-9.Google Scholar
  131. Mooney MR, Unger BT, Boland LL, et al. Therapeutic hypothermia after out-of-hospital cardiac arrest: evaluation of a regional system to increase access to cooling. Circulation 2011;124:206-14.PubMedCrossRefPubMedCentralGoogle Scholar
  132. Muftuoglu M, Olson A, Marin D, et al. Allogeneic BK Virus-Specific T Cells for Progressive Multifocal Leukoencephalopathy. N Engl J Med 2018;379:1443-1451.PubMedPubMedCentralCrossRefGoogle Scholar
  133. National Academies of Sciences, Engineering, and Medicine; Health and Medicine Division, Board on Health Sciences Policy, Committee on Preventing Dementia and Cognitive Impairment, et al. Preventing cognitive decline and dementia: a way forward. Washington, DC, National Academies Press, 2017.Google Scholar
  134. Nicholas R, Giannetti P, Alsanousi A, et al. Development of oral immunomodulatory agents in the management of multiple sclerosis. Drug Des Devel Ther 2011;5:255-74.PubMedPubMedCentralCrossRefGoogle Scholar
  135. Nierenberg NE, Thompson GR, Lewis JS, et al. Voriconazole use and pharmacokinetics in combination with interferon-gamma for refractory cryptococcal meningitis in a patient receiving low-dose ritonavir. Med Mycol 2010;48:532-6.PubMedCrossRefPubMedCentralGoogle Scholar
  136. Nishijima K, Ng YS, Zhong L, et al. Vascular endothelial growth factor-A is a survival factor for retinal neurons and a critical neuroprotectant during the adaptive response to ischemic injury. Am J Pathol 2007;171:53-67.PubMedPubMedCentralCrossRefGoogle Scholar
  137. Norman JP, Perry SW, Reynolds HM, et al. HIV-1 Tat Activates Neuronal Ryanodine Receptors with Rapid Induction of the Unfolded Protein Response and Mitochondrial Hyperpolarization. PLoS ONE 2008;3(11):e3731PubMedPubMedCentralCrossRefGoogle Scholar
  138. O’Connor P, Wolinsky JS, Confavreux C, et al. Randomized Trial of Oral Teriflunomide for Relapsing Multiple Sclerosis. N Engl J Med 2011;365:1293-03.PubMedCrossRefPubMedCentralGoogle Scholar
  139. Pachiappan A, Thwin MM, Weng Keong L, et al. ETS2 regulating neurodegenerative signaling pathway of human neuronal (SH-SY5Y) cells exposed to single and repeated low-dose sarin (GB). Chem Res Toxicol 2009;22:990-6.PubMedCrossRefPubMedCentralGoogle Scholar
  140. Palanichamy A, Jahn S, Nickles D, et al. Rituximab efficiently depletes increased CD20-expressing T cells in multiple sclerosis patients. J Immunol 2014;193:580-6.PubMedPubMedCentralCrossRefGoogle Scholar
  141. Palermo G, Ceravolo R, Bonuccelli U. Advances in the pharmacotherapeutic management of dementia with Lewy bodies. Expert Opin Pharmacother 2018;19:1643-53.PubMedCrossRefPubMedCentralGoogle Scholar
  142. Palmer AM. Teriflunomide, an inhibitor of dihydroorotate dehydrogenase for the potential oral treatment of multiple sclerosis. Curr Opin Invest Drugs 2010; 11:1313-23Google Scholar
  143. Pan HC, Yang DY, Ou YC, et al. Neuroprotective effect of atorvastatin in an experimental model of nerve crush injury. Neurosurgery 2010;67:376-89.PubMedCrossRefPubMedCentralGoogle Scholar
  144. Papadopoulou A, D’Souza M, Kappos L, Yaldizli O. Dimethyl fumarate for multiple sclerosis. Expert Opin Investig Drugs 2010;19:1603-12.PubMedCrossRefPubMedCentralGoogle Scholar
  145. Parihar VK, Limoli CL. Cranial irradiation compromises neuronal architecture in the hippocampus. PNAS 2013;110:12822-7.PubMedCrossRefPubMedCentralGoogle Scholar
  146. Pearce A, Lockwood C, van den Heuvel C, Pearce J. The use of therapeutic magnesium for neuroprotection during global cerebral ischemia associated with cardiac arrest and cardiac surgery in adults: a systematic review. JBI Database System Rev Implement Rep 2017;15:86-118.PubMedCrossRefPubMedCentralGoogle Scholar
  147. Perwein MK, Smestad JA, Warrington AE, et al. A Comparison of Human Natural Monoclonal Antibodies and Aptamer Conjugates for Promotion of CNS Remyelination: Where Are We Now and What Comes Next? Expert Opin Biol Ther 2018;18:545-560.PubMedCrossRefPubMedCentralGoogle Scholar
  148. Pihl-Jensen G, Tsakiri A, Frederiksen JL. Statin treatment in multiple sclerosis: a systematic review and meta-analysis. CNS Drugs 2015;29:277-91.PubMedCrossRefPubMedCentralGoogle Scholar
  149. Plavina T, Muralidharan KK, Kuesters G, et al. Reversibility of the effects of natalizumab on peripheral immune cell dynamics in MS patients. Neurology 2017;89:1584-93.PubMedPubMedCentralCrossRefGoogle Scholar
  150. Popugaev KA, Savin IA, Goriachev AS, et al. First experience of using CoolGard system in intensive care patients after neurosurgical interventions: series of 10 observations [Article in Russian]. Anesteziol Reanimatol 2011;2:42-9.Google Scholar
  151. Pozzilli C, Prosperini L, Borriello G. Treating multiple sclerosis with fingolimod or intramuscular interferon. Expert Opin Pharmacother 2010;11:1957-60.PubMedCrossRefPubMedCentralGoogle Scholar
  152. Procaccio V, Bris C, Chao de la Barca JM, et al. Perspectives of drug-based neuroprotection targeting mitochondria. Rev Neurol (Paris) 2014;170:390-400.CrossRefGoogle Scholar
  153. Pryce G, Riddall DR, Selwood DL, et al. Neuroprotection in Experimental Autoimmune Encephalomyelitis and Progressive Multiple Sclerosis by Cannabis-Based Cannabinoids. J Neuroimmune Pharmacol 2015;10:281-92.PubMedCrossRefPubMedCentralGoogle Scholar
  154. Rafei M, Hsieh J, Zehntner S, et al. A granulocyte-macrophage colony–stimulating factor and interleukin-15 fusokine induces a regulatory B cell population with immune suppressive properties. Nat Med 2009;15:1038-45.PubMedPubMedCentralCrossRefGoogle Scholar
  155. Rahgozar K, Wright E, Carrithers LM, et al. Mediation of protection and recovery from experimental autoimmune encephalomyelitis by macrophages expressing the human voltage-gated sodium channel NaV1.5. J Neuropathol Exp Neurol 2013;72:489-504.PubMedCrossRefPubMedCentralGoogle Scholar
  156. Rice CM, Whone AL, Walsh P, et al. Safety and Feasibility of Autologous Bone Marrow Cellular Therapy in Relapsing-Progressive Multiple Sclerosis. Clin Pharmacol Ther 2010;87:679-85.PubMedCrossRefPubMedCentralGoogle Scholar
  157. Rorsman I, Petersen C, Nilsson PC. Cognitive functioning following one-year natalizumab treatment: A non-randomized clinical trial. Acta Neurol Scand 2018;137:117-124.PubMedCrossRefPubMedCentralGoogle Scholar
  158. Rothhammer V, Kenison JE, Tjon E, et al. Sphingosine 1-phosphate receptor modulation suppresses pathogenic astrocyte activation and chronic progressive CNS inflammation. Proc Natl Acad Sci U S A 2017;114:2012-2017.PubMedPubMedCentralCrossRefGoogle Scholar
  159. Rush CA, Atkins HL, Freedman MS. Autologous Hematopoietic Stem Cell Transplantation in the Treatment of Multiple Sclerosis. Cold Spring Harb Perspect Med 2018;pii: a029082Google Scholar
  160. Sakowski SA, Heavener SB, Lunn JS, et al. Neuroprotection using gene therapy to induce vascular endothelial growth factor-A expression. Gene Ther 2009;16:1292-9.PubMedPubMedCentralCrossRefGoogle Scholar
  161. Salihoğlu M, Ay H, Cincik H, et al. Efficiency of hyperbaric oxygen and steroid therapy in treatment of hearing loss following acoustic trauma. Undersea Hyperb Med 2015;42:539-46.PubMedPubMedCentralGoogle Scholar
  162. Sayouri H, Boudier A, Vigneron C, et al. Hydrogen sulfide: A promising therapy in neuroprotection following cardiac arrest? Ann Pharm Fr 2015;73:401-10.PubMedCrossRefPubMedCentralGoogle Scholar
  163. Scannevin RH, Chollate S, Jung MY, et al. Fumarates promote cytoprotection of central nervous system cells against oxidative stress via the nuclear factor (erythroid-derived 2)-like 2 pathway. J Pharmacol Exp Ther 2012;341:274-84.PubMedCrossRefPubMedCentralGoogle Scholar
  164. Schampel A, Volovitch O, Koeniger T, et al. Nimodipine fosters remyelination in a mouse model of multiple sclerosis and induces microglia-specific apoptosis.Proc Natl Acad Sci U S A 2017 18;114:E3295-E3304CrossRefGoogle Scholar
  165. Schattling B, Steinbach K, Thies E, et al. TRPM4 cation channel mediates axonal and neuronal degeneration in experimental autoimmune encephalomyelitis and multiple sclerosis. Nature Medicine 2012;18:1805-11.PubMedCrossRefPubMedCentralGoogle Scholar
  166. Schreiber K, Magyari M, Sellebjerg F, et al. High-dose erythropoietin in patients with progressive multiple sclerosis: A randomized, placebo-controlled, phase 2 trial. Mult Scler 2017;23:675-685.PubMedCrossRefPubMedCentralGoogle Scholar
  167. Schreiner B, Becher B. Perspectives on cytokine-directed therapies in multiple sclerosis, Swiss Med Wkly 2015;145:w14199.PubMedPubMedCentralGoogle Scholar
  168. Schubert D, Currais A, Goldberg J, et al. Geroneuroprotectors: Effective Geroprotectors for the Brain. Trends in Pharmacological Sciences 2018;39:1004-1007.PubMedCrossRefPubMedCentralGoogle Scholar
  169. Schwartz BG, Kloner RA, Thomas JL, et al. Therapeutic hypothermia for acute myocardial infarction and cardiac arrest. Am J Cardiol 2012;110:461-6.PubMedCrossRefPubMedCentralGoogle Scholar
  170. Seidman MD, Tang W, Bai VU, et al. Resveratrol decreases noise-induced cyclooxygenase-2 expression in the rat cochlea. Otolaryngol Head Neck Surg 2013;148:827-33.PubMedCrossRefPubMedCentralGoogle Scholar
  171. Shan X, Chi L, Ke Y, et al. Manganese superoxide dismutase protects mouse cortical neurons from chronic intermittent hypoxia-mediated oxidative damage. Neurobiol Dis 2007;28:206-15.PubMedPubMedCentralCrossRefGoogle Scholar
  172. Shankaran S, Pappas A, McDonald SA, et al. Childhood Outcomes after Hypothermia for Neonatal Encephalopathy. N Engl J Med 2012;366:2085-92.PubMedPubMedCentralCrossRefGoogle Scholar
  173. Shibata SB, Cortez SR, Beyer LA, et al. Transgenic BDNF induces nerve fiber regrowth into the auditory epithelium in deaf cochleae. Exp Neurol 2010;223:464-72.PubMedPubMedCentralCrossRefGoogle Scholar
  174. Shirani A, Zhao Y, Karim ME, et al. Association between use of interferon Beta and progression of disability in patients with relapsing-remitting multiple sclerosis. JAMA 2012;308:247-56.PubMedPubMedCentralGoogle Scholar
  175. Sicurelli F, Carluccio MA, Toraldo F, et al. Clinical and biochemical improvement following HSCT in a patient with MNGIE: 1-year follow-up. J Neurol 2012;259:1985-7.PubMedCrossRefPubMedCentralGoogle Scholar
  176. Siddarth P, Burggren AC, Eyre HA, et al. Sedentary behavior associated with reduced medial temporal lobe thickness in middle-aged and older adults. PLoS ONE 2018;13: e0195549.PubMedPubMedCentralCrossRefGoogle Scholar
  177. Singhmar P, Huo X, Li Y, et al. Orally active Epac inhibitor reverses mechanical allodynia and loss of intraepidermal nerve fibers in a mouse model of chemotherapy-induced peripheral neuropathy. Pain 2018;159:884-93.PubMedPubMedCentralCrossRefGoogle Scholar
  178. Smith CR, Parsons JT, Zhu J, Spiess BD. The effect of intravenous perfluorocarbon emulsions on whole-body oxygenation after severe decompression sickness. Diving Hyperb Med 2012;42:10-7.PubMedPubMedCentralGoogle Scholar
  179. Sperling MA. Fluid Composition, Infusion Rate, and Brain Injury in Diabetic Ketoacidosis. N Engl J Med 2018;378:2336-8.PubMedCrossRefPubMedCentralGoogle Scholar
  180. Stegbauer J, Lee DH, Seubert S, et al. Role of the renin-angiotensin system in autoimmune inflammation of the central nervous system. PNAS 2009;106:14942-7.PubMedCrossRefPubMedCentralGoogle Scholar
  181. Talmage GD, Coppes OJM, Javed A, Bernard J. Natalizumab stabilizes physical, cognitive, MRI, and OCT markers of disease activity: a prospective, non-randomized pilot study. PLoS One 2017;12(4):e0173299.PubMedPubMedCentralCrossRefGoogle Scholar
  182. Terni B, Rey MJ, Boluda S, et al. Mutant ubiquitin and p62 immunoreactivity in cases of combined multiple system atrophy and Alzheimer’s disease. Acta Neuropathol 2007;113:403-16.PubMedCrossRefPubMedCentralGoogle Scholar
  183. The ACCORD Study Group and ACCORD Eye Study Group. Effects of Medical Therapies on Retinopathy Progression in Type 2 Diabetes. NEJM 2010;363:233-244.CrossRefGoogle Scholar
  184. Theurl M, Lener D, Albrecht-Schgoer K, et aal. Gene therapy with the angiogenic neuropeptide secretoneurin ameliorates experimental diabetic neuropathy. FASEB J 2018;32:4815-4823.PubMedCrossRefPubMedCentralGoogle Scholar
  185. Tona Y, Hamaguchi K, Ishikawa M, et al. Therapeutic potential of a gamma-secretase inhibitor for hearing restoration in a guinea pig model with noise-induced hearing loss. BMC Neuroscience 2014;15:66.PubMedPubMedCentralCrossRefGoogle Scholar
  186. Trevino K, McClintock SM, Husain MM. A review of continuation electroconvulsive therapy: application, safety, and efficacy. J ECT 2010;26:186-95.PubMedCrossRefPubMedCentralGoogle Scholar
  187. Tselis A, Khan OA, Lisak RP. Approaches to neuroprotective strategies in multiple sclerosis. Expert Opin Pharmacother 2010;11: 2869-78.PubMedCrossRefGoogle Scholar
  188. Tu S, Akhtar MW, Nakanishi N. NitroSynapsin therapy for a mouse MEF2C haploinsufficiency model of human autism. Nature Communications 2017;8:1488PubMedPubMedCentralCrossRefGoogle Scholar
  189. Upadhya D, Hattiangady B, Castro OW, et al. Human induced pluripotent stem cell-derived MGE cell grafting after status epilepticus attenuates chronic epilepsy and comorbidities via synaptic integration. Proc Natl Acad Sci U S A 2019;116:287-296.PubMedCrossRefGoogle Scholar
  190. Verghese PB, Sasakib Y, Yang D, et al. Nicotinamide mononucleotide adenylyl transferase 1 protects against acute neurodegeneration in developing CNS by inhibiting excitotoxic-necrotic cell death. Proc Natl Acad Sci U S A 2011;108:19054-9.PubMedPubMedCentralCrossRefGoogle Scholar
  191. Villapol S, Saavedra JM. Neuroprotective effects of angiotensin receptor blockers. Am J Hypertens 2015;28:289-99.PubMedCrossRefGoogle Scholar
  192. Walter EJ, Carraretto M. The neurological and cognitive consequences of hyperthermia. Crit Care 2016;20:199.Google Scholar
  193. Wang JT, Medress ZA, Vargas ME, Barre BE. Local axonal protection by WldS as revealed by conditional regulation of protein stability. Proc Natl Acad Sci U S A 2015;112:10093-100.CrossRefGoogle Scholar
  194. Warrington JP, Csiszar A, Johnson DA, et al. Cerebral microvascular rarefaction induced by whole brain radiation is reversible by systemic hypoxia in mice. Am J Physiol Heart Circ Physiol 2011;300: H736–744.PubMedCrossRefPubMedCentralGoogle Scholar
  195. Warrington JP, Csiszar A, Mitschelen M, et al. Whole brain radiation-induced impairments in learning and memory are time-sensitive and reversible by systemic hypoxia. PLoS ONE 2012;7: e30444.PubMedPubMedCentralCrossRefGoogle Scholar
  196. Watchko JF, Tiribelli C. Bilirubin-induced neurologic damage − mechanisms and management approaches. N Engl J Med 2013;369:2021-30.PubMedCrossRefPubMedCentralGoogle Scholar
  197. Waubant E, Pelletier D, Mass M, et al. Randomized controlled trial of atorvastatin in clinically isolated syndrome: the STAyCIS study. Neurology 2012;78:1171-8.PubMedPubMedCentralCrossRefGoogle Scholar
  198. Weigel KJ, Lynch SG, Levine SM, et al. Iron chelation and multiple sclerosis. ASN Neuro 2014;6:e00136.PubMedPubMedCentralGoogle Scholar
  199. Wiberg S, Hassager C, Thomsen JH, et al. GLP-1 analogues for neuroprotection after out-of-hospital cardiac arrest: study protocol for a randomized controlled trial. Trials 2016;17:304.Google Scholar
  200. Willoughby RE Jr. A cure for a rabies? Sci Am 2007;296:88-95.PubMedCrossRefPubMedCentralGoogle Scholar
  201. Wilson AD, Hart A, Brännström T, et al. Delayed acetyl-L-carnitine administration and its effect on sensory neuronal rescue after peripheral nerve injury. J Plast Reconstr Aesthet Surg 2007;60:114-8.PubMedCrossRefPubMedCentralGoogle Scholar
  202. Wilson RS, Leurgans SE, Boyle PA, et al. Neurodegenerative basis of age-related cognitive decline. Neurology 2010;75:1070-8.PubMedPubMedCentralCrossRefGoogle Scholar
  203. Wolfsdorf JI, Glaser N, Agus M, et al. Diabetic ketoacidosis and hyperglycemic hyperosmolar state: a consensus statement from the International Society for Pediatric and Adolescent Diabetes (ISPAD). Pediatr Diabetes 2018;19 Suppl 27:155-177.PubMedCrossRefPubMedCentralGoogle Scholar
  204. Wu Q, Chen W, Sinha B, et al. Neuroprotective agents for neonatal hypoxic-ischemic brain injury. Drug Discov Today 2015;20:1372-81.PubMedCrossRefPubMedCentralGoogle Scholar
  205. Wu YW, Bauer LA, Ballard RA, et al. Erythropoietin for neuroprotection in neonatal encephalopathy: safety and pharmacokinetics. Pediatrics 2012;130:683-91.PubMedPubMedCentralCrossRefGoogle Scholar
  206. Yadav V, Bourdette DN, Bowen JD, et al. Recombinant T-Cell Receptor Ligand (RTL) for Treatment of Multiple Sclerosis: A Double-Blind, Placebo-Controlled, Phase 1, Dose-Escalation Study. Autoimmune Dis 2012;2012:954739.PubMedPubMedCentralGoogle Scholar
  207. Yan R, Zhang J, Park HJ, et al. Synergistic neuroprotection by coffee components eicosanoyl-5-hydroxytryptamide and caffeine in models of Parkinson’s disease and DLB. Proc Natl Acad Sci U S A 2018;115:E12053-E12062.PubMedPubMedCentralCrossRefGoogle Scholar
  208. Yang D, Nemkul N, Shereen A, et al. Therapeutic administration of plasminogen activator inhibitor-1 prevents hypoxic-ischemic brain injury in newborns. J Neurosci 2009;29:8669-74.PubMedPubMedCentralCrossRefGoogle Scholar
  209. Zeiler FA, Jackson AC. Critical Appraisal of the Milwaukee Protocol for Rabies: This Failed Approach Should Be Abandoned. Can J Neurol Sci 2016;43:44-51.PubMedCrossRefPubMedCentralGoogle Scholar
  210. Zhou BY, Lu GJ, Huang YQ, et al. Efficacy of hyperbaric oxygen therapy under different pressures on neonatal hypoxic-ischemic encephalopathy. Zhongguo Dang Dai Er Ke Za Zhi 2008;10:133-5.PubMedPubMedCentralGoogle Scholar
  211. Zhu Y, Fenik P, Zhan G, et al. Eif-2a protects brainstem motoneurons in a murine model of sleep apnea. J Neurosci 2008;28:2168-78PubMedCrossRefPubMedCentralGoogle Scholar
  212. Zou Y, Corniola R, Leu D, et al. Extracellular superoxide dismutase is important for hippocampal neurogenesis and preservation of cognitive functions after irradiation. PNAS 2012;109:21522-7.PubMedCrossRefPubMedCentralGoogle Scholar
  213. Zuercher P, Springe D, Grandgirard D, et al. A randomized trial of the effects of the noble gases helium and argon on neuroprotection in a rodent cardiac arrest model. BMC Neurol 2016;16:43.PubMedPubMedCentralCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2019

Authors and Affiliations

  • Kewal K. Jain
    • 1
  1. 1.Jain PharmaBiotechBaselSwitzerland

Personalised recommendations